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Toxoplasmosis is a foodborne disease caused by Toxoplasma gondii, an obligate
intracellular parasite. Severe symptoms occur in the immunocompromised patients and
pregnant women leading to fatality and abortions respectively. Vaccination development
is essential to control the disease. The T. gondii dense granule antigen 2 and 5 (GRA2
and GRA5) have been targeted in this study because these proteins are essential to the
development of parasitophorous vacuole (PV), a specialized compartment formed within
the infected host cell. PV is resistance to host cell endosomes and lysosomes thereby
protecting the invaded parasite. Recombinant dense granular proteins, GRA2 (rGRA2)
and GRA5 (rGRA5) were cloned, expressed, and purified in Escherichia coli, BL21 (DE3)
pLysS. The potential of these purified antigens as subunit vaccine candidates against
toxoplasmosis were evaluated through subcutaneous injection of BALB/c mice followed
by immunological characterization (humoral- and cellular-mediated) and lethal challenge
against virulent T. gondii RH strain in BALB/c mice. Results obtained demonstrated
that rGRA2 and rGRA5 elicited humoral and cellular-mediated immunity in the mice.
High level of IgG antibody was produced with the isotype IgG2a/IgG1 ratio of ≈0.87
(p < 0.001). Significant increase (p < 0.05) in the level of four cytokines (IFN-γ, IL-
2, IL-4, and IL-10) was obtained. The antibody and cytokine results suggest that a
mix mode of Th1/Th2-immunity was elicited with predominant Th1-immune response
inducing partial protection against T. gondii acute infection in BALB/c mice. Our findings
indicated that both GRA2 and GRA5 are potential candidates for vaccine development
against T. gondii acute infection.
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INTRODUCTION
Toxoplasma gondii (T. gondii) is a ubiquitous and obligate intracellular protozoan parasite capable
of infecting a broad range of warm-blooded hosts (Dubey, 2010), causing a disease known as
toxoplasmosis. Toxoplasmosis is a common infection globally distributed affecting up to one-
third of the world’s human population (Jackson and Hutchison, 1989). It poses danger to the
AIDS patients and pregnant women where fatality and abortions can result respectively. T. gondii
infection also causes abortions in livestock especially sheep and goats, leading to great economic
losses in livestock and food industry (Buxton, 1998).
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Infected patients are commonly treated with pyrimethamine,
sulphadiazine and spiramycin (during pregnancy) but these
drugs are unable to eliminate the parasites completely (Hill
and Dubey, 2002; Montoya and Liesenfeld, 2004). The problem
of parasites eradication, disease reactivation, toxic effects and
emerging drug resistance in parasites makes drug treatment
unreliable for long term treatment (Bhopale, 2003; Kur et al.,
2009; Innes, 2010). Development of effective vaccines against
toxoplasmosis is thus needed to fight against the parasite. To
date, Toxovax is the only available vaccine in the market for
preventing toxoplasmosis in domestic animals especially sheep
and goats. However, this vaccine is not widely acceptable for
human use due to the high possibility of regaining the parasite’s
pathogenicity (Chen et al., 2009), side effects and high cost of
production (Ismael et al., 2003). Production of safe recombinant
vaccines is made possible through recombinant DNA technology.
Development of protein-based vaccines are basically safer and
more specific in boosting the immune response of the recipients
by presenting only selected immunogenic antigens instead of
the whole parasite (Schaap et al., 2007). The common route
of purified recombinant protein injection is via subcutaneous
tissue. Upon injection, the proteins will be taken up by circulating
antigen presenting cell (APC) such as macrophage. The proteins
will then be processed into peptide-MHC class II complex
within APC before being presented on the cell surface to CD4+
helper T cells, stimulating humoral-mediated immunity (Th2)
resulting in antibody production. Difficulties in generating Th1
immunity can be overcome by formulating the recombinant
proteins with appropriate adjuvants as they play important role
in directing the desired Th1/Th2 profiles (Kur et al., 2009;
Bruna-Romero et al., 2012). For example, formulation of alum
(Th2 inducer) and IL-12 (Th1 inducer) result in a strong
Th1 activity (Schaap et al., 2007). Other adjuvants that are
commonly used in subcutaneous injection are Freund’s complete
adjuvant (FCA), Freund’s incomplete adjuvant (FIA), liposomes
and IL-12.
Toxoplasma gondii infection begins when the tachyzoites
invade host cells. Uncontrolled replication of the tachyzoites
leads to rupturing of the infected cells thereby releasing new
parasites to invade neighboring cells. The parasite remains
protected within a parasitophorous vacuole (PV), a specialized
compartment formed within the infected host cell during and
after invasion. Dense granules (GRAs) are T. gondii specialized
secretory organelles involved in PV development whereby
the antigens helped in the maturation and modification of
both PV and PV membrane (Nam, 2009). GRAs are the
major components of both vacuole surrounding tachyzoites and
encysted bradyzoites (Capron and Dessaint, 1988; Cesbron-
Delauw and Capron, 1993) which have been identified as
potential vaccines (Scorza et al., 2003; Hiszczynska-Sawicka et al.,
2011; Sun et al., 2011).
GRA2 contributes to the formation of intravacuolar network
in PV, allowing proteins and nutrients transportation to nourish
the parasites while GRA5 helps to inhibit apoptosis of the infected
cells thereby protecting the parasites during cell invasion (Feng
et al., 2002; Nam, 2009). Both GRA2 and GRA5 are expressed
throughout the whole intermediate host life cycle ofT. gondii thus
preventing stage-limited protection against toxoplasmosis (Tilley
et al., 1997; Zhou et al., 2007).
Several studies had been conducted on the evaluation
of multi-component vaccine candidate incorporating GRA2 or
GRA5 with other potential genes against toxoplasmosis (Zhou
et al., 2007; Igarashi et al., 2008a; Xue et al., 2008; Liu et al.,
2009). However, limited number of study had been performed on
these two target genes as single antigen vaccine especially GRA5.
The only report on rGRA2 expressed in Escherichia coli as single
subunit vaccine candidate investigated its efficacy against chronic
toxoplasmosis based on the T. gondii brain cysts counts (Golkar
et al., 2007). Nevertheless, protective effect conferred by the same
antigen against lethal parasitic infection of type I virulent strain
has not been reported yet. In this study, recombinant GRA2 and
GRA5 proteins were subjected to mice immunization study as
single antigen subunit vaccine candidates against acute T. gondii
infection in BALB/c mice.
MATERIALS AND METHODS
Mice
Six- to eight-week old female BALB/c mice were purchased from
Monash University Sunway Campus. The mice were maintained
in a pathogen free environment and were fed ad lib with
commercial food pellets and water.
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Malaya, Faculty of
Medicine (Permit Number: 2014-06-03/PARA/R/CXT).
Parasites Propagation and Harvest
Toxoplasma gondii tachyzoites of the virulent wild-type RH strain
were provided by the Department of Parasitology, University of
Malaya, Kuala Lumpur, Malaysia. They were propagated in vitro
involving infection of Human Foreskin Fibroblast (HFF) cells.
DMEM complete medium was replaced with parasite infection
medium 12–16 h pre-infection when the growth of HFF cells
reached 80–90% confluence. Freshly isolated or frozen parasites
were washed with sterile phosphate-buffered saline (PBS) and
resuspended in parasite infection medium before infecting the
HFF cells. After 24 h of incubation in the CO2 incubator, the
infected cells were replaced with new parasite infection medium
in order to remove free floating tachyzoites. Incubation was
continued until the lysis of the infected cells triggered by the
actively replicating tachyzoites thereby releasing them into the
medium.
During lysis of the infected HFF cells, erupted tachyzoites and
the infected cells were harvested with a cell scraper (TPP, USA).
The entire cell suspension was transferred to a syringe attached
to a 25 gage needle which was placed into a 50 ml polypropylene
tube beforehand. The cell suspension was forced to pass through
the needle by the plunger to ensure the release of tachyzoites from
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the intact infected cells. The act was repeated twice followed by
two times of washing with sterile PBS whereby the cell suspension
was centrifuged at 1,000× g for 15 min between each wash. After
the last wash, the pellet obtained was resuspended in sterile PBS
before filtering through 3 µm polycarbonate membrane (Merck,
USA). The filtrate containing only the parasites was sedimented
and resuspended in sterile PBS prior to usage.
Recombinant GRA2 and GRA5 Proteins
Production
Recombinant GRA2 and GRA5 plasmids were constructed and
the sequences were verified. Heterologous expression of the
positive clones was performed in BL21 (DE3) pLysS followed
by affinity purification. Identity of the purified recombinant
proteins were validated through MALDI-TOF MS analysis before
subjected to vaccination study. The entire procedures were
described thoroughly in our previous report (Ching et al., 2015).
Immunization Regime
Six- to eight-week old female inbred BALB/c mice were
divided into four immunization groups with 13 mice in
each group; two negative controls: PBS and pRSET B, two
protein groups: rGRA2 and rGRA5. Three injections were
administered subcutaneously with final protein dose of 10 µg
at 2 weeks intervals. Injection samples were emulsified with
complete/incomplete Freud’s adjuvant (C/IFA) at 1:1 ratio before
immunizing the mice. Blood (50–100 µl) were collected from
the immunized mice through tail-bleeding on day 0, 14, 28,
and 42.
Evaluation of Humoral Response
Mice serum samples harvested were analyzed by western blot
assay (Ching et al., 2015) and in-house ELISA against the purified
recombinant proteins to detect the presence of antigen-specific
IgG antibodies and to determine antibody titers.
IgG Titer and Subclass Determination
The 96-well flat bottom microplate was coated overnight at 4◦C
with 10 µg/ml rGRA2 or rGRA5 diluted in 100 µl coating
buffer. The antigen solutions were aspirated and the wells
were washed three times with 0.05% PBS-T after overnight
incubation. The subsequent incubation steps were all carried
out at 37◦C. Non-specific binding sites of the wells were
blocked by incubation with 200 µl of 10% blocking buffer
for 1 h. The blocking buffer was then aspirated and the plate
was washed thrice followed by incubation with 100 µl of
serially diluted mice sera (control and vaccinated) for another
1 h to determine the optimal working dilution. The plate
was washed again in the same way. Bound antigen-specific
IgG was detected through incubation with 100 µl of diluted
HRP-conjugated goat anti-mouse IgG (1:2000) for 1 h. The
plate was washed five times and the enzymatic reaction was
developed by addition of 100 µl 3,3′,5,5′-Tetramethylbenzidine
(TMB), a chromogenic substrate and was incubated for 10–
15 min at RT. The reaction was eventually stopped with 2 M
of sulphuric acid and the absorbance was measured at 450 nm
with microplate reader. Primary and secondary antibodies were
diluted in 10% blocking buffer. All samples were run in triplicates.
Vaccinated mice sera were considered positive if the mean optical
density (OD) of triplicate determinations was greater than the
cut-off limit of the negative control groups; cut-off = mean
OD + 2(standard deviation). The entire steps were repeated for
IgG subclass determination assay whereby different secondary
antibodies involved were HRP-conjugated goat anti-mouse IgG1
and IgG2a.
In Vitro Splenocyte Proliferation Assay
Three mice per group were euthanized with CO2 and spleens
were harvested aseptically two weeks after final immunization.
Single cell suspension was prepared by mashing the spleen
over a 70 µm cell strainer and washed with 10 ml RPMI
complete medium (CM) before subjected to centrifugation. All
centrifugation steps were performed at 1,500 rpm for 10 min.
Cell pellet obtained was resuspended with 5 ml of ACK lysis
buffer and incubated for 5 min at RT. Five minute later;
the cell suspension was washed with 20 ml CM and was
centrifuged again. This step was repeated with 10 ml CM.
Cell pellet obtained was eventually resuspended in 10 ml CM.
Splenocytes were cultured in 96-well flat bottom microplate
with cell density of 2 × 105 cells/well in triplicates. The cells
were induced with culture medium alone (negative control),
10 µg/ml rGRA2 or rGRA5 or 5 µg/ml con A (positive control)
before incubated at 37◦C in a 5% CO2 incubator for 24, 72,
and 96 h.
Splenocytes proliferation was analyzed with MTT Cell
Proliferation Kit at 72 h post-incubation according to the
instruction’s manual. Briefly, MTT labeling reagents was added
into each well of cells and were incubated for 4 h followed by
incubation overnight with 100 µl of Solubilization solution. The
plate was read at 570 nm with microplate reader the next day.
Stimulation index (S1)
= mean OD570 values of stimulated cells
mean OD570 values of unstimulated cells
Cytokine Assays
Splenocytes cultured and incubated at different time point (24,
72, and 96 h) were subjected to centrifugation at 2,000 × g
for 20 min. Culture supernatants were collected for various
cytokine assays such as IFN-γ, IL-2, IL-4 and IL-10 assays.
These assays were performed in accordance with the instruction’s
manuals.
Mice Challenge
The remaining vaccinated and control mice were subjected to
lethal parasitic challenge study through intraperitoneal injection
of 1 × 103 live tachyzoites of T. gondii virulent RH strain.
Mortality rate of the mice were monitored and recorded
twice daily whereby the infected mice were observed for end-
point criteria that is when they were heavily infected, showing
symptoms of sluggish movement, hunched back posture, ruﬄed
and thinning hair coat as well as obvious reduced food and
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FIGURE 1 | Qualitative detections of total specific anti-GRAs IgG antibodies in mice sera. Western blots of purified recombinant proteins (rGRA2 or/and
rGRA5) with sera of the immunized mice. Lane 1 contained PageRuler Prestained Protein Ladder. Lane 2–5 were incubated with sera of PBS-injected mice, lane 6–9
were incubated with sera of pRSET B-injected mice, lane 10–13 were incubated with sera of rGRA2-immunized mice and lane 14–17 were incubated with sera of
rGRA5-immunized mice. The 4 sera represented sera collected at week 0, 2, 4, and 6 post-prime injections. The 30 kDa purified rGRA2 and 20 kDa purified rGRA5
were first detected at week 2 (lane 11 and 15 respectively) followed by an increase in the band intensity at week 4 and 6. No bands were observed in the mice sera
of the two control groups.
water consumption. The heavily infected mice that reached end-
point criteria were humanely killed by exposure to a gradually
increasing concentration of carbon dioxide (CO2) inside a closed
chamber.
Statistical Analysis
Significance levels of the differences between groups of mice
were analyzed through Student’s t-test or analysis of variance
(ANOVA). P< 0.05 indicates statistical significance. The survival
rate was calculated based on χ2 (chi-square) test while the
survival graph was drawn based on Kaplan–Meier method
(Kaplan and Meier, 1958).
RESULTS
IgG Antibody Detection
Total specific anti-GRA2 and anti-GRA5 IgG antibodies were
detected in the sera collected from the mice immunized
with rGRA2 and rGRA5 respectively through SDS-PAGE/WB
(Figure 1) and ELISA (Figure 2; Table 1) against purified
recombinant proteins. Faint protein bands with target size of 30
and 20 kDa were observed at week 2 after prime injection of
mice with rGRA2 and rGRA5 respectively as shown in Figure 1.
The intensity increased at week 4 and 6 following first and
second booster injections. However, antibody detection was not
observed in Native-PAGE/WB (data not shown). Meanwhile,
Figure 2 also showed the same phenomena whereby significantly
higher levels of IgG antibodies were observed in the recombinant
protein-vaccinated groups compared to two control groups
(p < 0.001) and the level gradually elevated with successive
immunizations. There was no statistical difference between the
two control groups at week 2 and 4 (p > 0.05). However,
IgG level in pRSET B-injected group was found significantly
FIGURE 2 | Quantitative detections of total specific anti-GRAs IgG
antibodies in mice sera. Total anti-GRAs IgG antibodies in mice sera were
detected and evaluated by ELISA. Sera were collected from each mouse
group one day before each immunization. Data are expressed as mean
OD450 ± SD (n = 3). Statistical differences are represented by ∗ (significant;
p < 0.05) and ∗∗∗ (highly significant; p < 0.001) in comparison with the
control groups (PBS or pRSET B).
higher than that of PBS-injected group (p < 0.05) at week
6 post-prime injection. The level of IgG antibodies in mice
sera collected from rGRA5-vaccinated group was significantly
higher than that of rGRA2-vaccinated group (p < 0.001)
at week 4 but both groups reached highest level 2 weeks
after the last injection (week 6) without statistical difference
(p > 0.05). These results indicated that both recombinant
GRA2 and GRA5 proteins are immunogenic and capable of
stimulating significantly strong humoral immune response in
the respective vaccinated mice compared to the negative control
groups.
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TABLE 1 | Specific anti-GRAs IgG antibody profile in sera collected from
the immunized BALB/c mice 2 weeks after last injection.
Group (n = 3) OD450
IgG IgG1 IgG2a
rGRA2 1.0330 ± 0.0645∗∗∗ 2.9760 ± 0.2025∗∗∗ 2.5850 ± 0.0303∗∗∗
rGRA5 1.0370 ± 0.0679∗∗∗ 3.0770 ± 0.0528∗∗∗ 2.6820 ± 0.0768∗∗∗
pRSET B 0.1267 ± 0.0170∗ 0.0801 ± 0.0020 0.0686 ± 0.0033
PBS 0.0540 ± 0.0007 0.1256 ± 0.0060 0.0717 ± 0.0078
Data are expressed as mean ± SD. Statistical differences are represented by ∗
(significant; p < 0.05) and ∗∗∗ (highly significant; p < 0.001) in comparison with the
control groups (PBS or pRSET B). Each group consisted of three mice.
IgG Titer Determination
Antibody titer is a quantitative measurement of the amount
of antibody capable of recognizing the respective epitope. It
is usually expressed as reciprocal of the highest dilution with
an OD450 greater than the positive cut-off value of IgG
(mean + 2 SD) relative to the control mice sera at the same
dilution. Antibody titer of both the anti-GRA2 and anti-GRA5
IgG was determined to range from 1:409,600 to 1:819,200 by
ELISA.
IgG Antibody Isotypes Determination
Polyclonal antibody isotypes (IgG1 and IgG2a) in the immunized
BALB/c mice sera were further assessed by ELISA in order
to identify type of immunity being triggered. The levels of
specific anti-GRAs IgG1 and IgG2a being produced are depicted
in Figure 3 and tabulated in Table 1. Generally, the level of
IgG isotypes present in the sera of the two vaccinated mice
groups were highly significantly greater than that of the two
control groups (p< 0.001). No statistical difference was observed
between the two control groups (p > 0.05) and also between
the two vaccinated groups (p > 0.05). On top of that, it was
FIGURE 3 | IgG isotypes determination in the immunized BALB/c mice
sera. Polyclonal antibody isotypes (IgG1 and IgG2a) in the immunized mice
sera were determined by ELISA. Sera from each mouse group were collected
2 weeks after the last injection. Data are expressed as mean OD450 ± SD
(n = 3). Statistical difference is represented by ∗∗∗ (highly significant;
p < 0.001) in comparison with the control groups (PBS or pRSET B).
shown that high levels of two IgG isotypes were detected in all the
rGRA2- and rGRA5-immunized mice sera, with slightly higher
level of IgG1 compared to IgG2a, giving rise to an IgG2a/IgG1
ratio of <1 (≈0.87). The result obtained indicated that both Th1
and Th2 immune responses were driven in all the vaccinated
mice.
In Vitro Splenocytes Proliferation Assay
Antigen-specific proliferative response of splenocytes from each
mice group to rGRA2 or/and rGRA5 stimulus was determined
using MTT assay and represented by the SI value as illustrated
in Figure 4 and Table 2. Generally, significantly higher SI
value was observed in the recombinant protein-vaccinated
groups compared to the control groups (p < 0.05). On top of
that, splenocytes from rGRA5-vaccinated mice had significantly
stronger proliferation compared to that of rGRA2-vaccinated
mice in response to their respective stimulus (p < 0.05).
Nevertheless, there was no statistical difference between the two
control groups (p> 0.05). Meanwhile, SI value for all mice groups
had comparable levels in response to the mitogen conA. These
results indicated that T lymphocytes of the vaccinated mice were
successfully stimulated.
Cytokine Production Assay
Results obtained showed that splenocytes of the vaccinated mice
produced significantly higher level of IFN-γ and IL-2 compared
to the control groups (p < 0.05) as demonstrated in Figure 5
and Table 2. No statistical difference was observed between two
vaccinated groups (p > 0.05) and between two control groups
(p> 0.05). In contrast, relatively low levels of IL-4 and IL-10 were
released by the stimulated splenocytes of the mice immunized
with rGRA2 and rGRA5 (Figure 6; Table 2). Undetectable level of
FIGURE 4 | In vitro splenocytes proliferation response in mice. Spleen
lymphocytes were harvested from mice immunized with rGRA2, rGRA5,
pRSET B and PBS 2 weeks after last injection. The splenocytes were cultured
and stimulated with the respective recombinant proteins. Proliferative
response was measured by MTT assay. Data are expressed as mean
stimulation index (SI) ± SD (n = 3). Statistical difference is represented by
∗(p < 0.05) in comparison with the control groups (PBS or pRSET B).
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TABLE 2 | Characterization of cellular-mediated immunity in the vaccinated mice.
Group (n = 3) Proliferation (SI) Cytokine level (pg/ml)
IFN-γ IL-2 IL-4 IL-10
rGRA2 1.973 ± 0.1589∗ 4645 ± 1032∗ 1527 ± 247∗ 9.989 ± 2.231 121.6 ± 43.94∗
rGRA5 2.414 ± 0.2674∗ 4724 ± 372.5∗ 1232 ± 95.07∗ 25.46 ± 11.98∗ 178.3 ± 27.71∗
pRSET B 1.514 ± 0.0447 197.4 ± 61.45 146 ± 42.01 Undetectable 61.55 ± 16.18
PBS 1.549 ± 0.0345 142.7 ± 77.15 123 ± 13.67 Undetectable 26.98 ± 8.667
SI stands for stimulation index. IFN-γ activity was assayed at 96 h, IL-2 and IL-4 activities were assayed at 24 h, and IL-10 activity was assayed at 72 h. Undetectable
IL-4 level was observed in the stimulated splenocytes culture supernatant of the negative control mice groups. Data are expressed as mean ± SD (n = 3). Statistical
difference is represented by ∗ (p < 0.05) in comparison with the control groups (PBS or pRSET B).
IL-4 was observed in the control groups (Table 2). However, IL-
10 level produced by splenocytes from the recombinant protein-
vaccinated mice was significantly higher compared to PBS and
pRSET B-injected mice (p < 0.05). Production of huge amount
of IFN-γ and IL-2 and relatively low level of IL-4 and IL-
10 indicated that Th1 immune response was favored in the
vaccinated mice.
Protective Efficacy of Recombinant
Protein Vaccination in BALB/c Mice
Protective efficacy of recombinant GRA2 and GRA5 proteins
in the immunized BALB/c mice were evaluated against lethal
challenge with T. gondii. The survival rates of the four
challenged mice groups were illustrated in Figure 7. It was
shown that the two vaccinated mice groups had significantly
prolonged survival rates as compared to the two control
mice groups (PBS and pRSET B) (p < 0.05). All PBS- and
pRSET B-injected mice succumbed to the parasite infection
on day 6 (median survival of 6 days) and day 9 (median
survival of 8 days) respectively. Meanwhile, rGRA2- and rGRA5-
immunized mice died within 8–18 days post-infection with the
median survival of 16.5 and 16 days respectively. Although
all the immunized mice died on day 18, but these two
subunit vaccines were successfully demonstrated to increase the
survival rates of the vaccinated BALB/c mice against T. gondii
infection.
DISCUSSION
Subunit vaccination is generally known for its efficacy in inducing
humoral immune responses against extracellular pathogens
through antibody generation which is favored by T helper 2
(Th2) related responses. Th1 and Th2 responses are characterized
by differences in cytokine production and by antibody isotype
(Snapper and Paul, 1987; Gazzinelli et al., 1991; Germann et al.,
1995; Bessieres et al., 1997). However, T. gondii is an intracellular
parasite, thus an immune response mediated by CD4+ Th1 and
CD8+ cytotoxic T cells are the main components required to
combat this parasitic infection (Denkers and Gazzinelli, 1998).
Immunization using animal model with recombinant expressed
protein alone is weakly immunogenic (Sloat et al., 2010) and often
elicited a mixed Th1/Th2-like response with higher tendency
of IgG1 isotype production, driving predominantly Th2-like
response (Echeverria et al., 2006; Dziadek et al., 2009, 2012; Sun
et al., 2014). Therefore, addition of Th1-directing adjuvant such
as Complete Freund’s adjuvant (CFA) was used in this study. This
FIGURE 5 | (A,B) IFN-γ and IL-2 production by the stimulated splenocytes of the immunized mice. Culture supernatants from the antigen-stimulated immunized
mice splenocytes were harvested at 96 and 24 h post-incubation for the evaluation of (A) IFN-γ and (B) IL-2 production respectively via ELISA. Data are expressed
as mean ± SD (n = 3). Statistical difference is represented by ∗(p < 0.05) in comparison with the control groups (PBS or pRSET B).
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FIGURE 6 | (A,B) IL-4 and IL-10 production by the stimulated splenocytes of the immunized mice. Culture supernatants from the antigen-stimulated immunized
mice splenocytes were harvested at 24 and 72 h post-incubation for the evaluation of (A) IL-4 and (B) IL-10 production respectively via ELISA. Data are expressed
as mean ± SD (n = 3). Statistical difference is represented by ∗(p < 0.05) in comparison with the control groups (PBS or pRSET B).
FIGURE 7 | Survival rate of the immunized mice. All four groups of the immunized mice (PBS, pRSET B, rGRA2, rGRA5) were subjected to lethal challenge with
1000 live tachyzoites of T. gondii virulent RH strain 2 weeks after the last immunization. Mice immunized with rGRA2 and rGRA5 exhibited a significant increase in
the survival days (median survival of 16.5 and 16 days respectively) in comparison to the control mice injected with PBS and pRSET B (median survival of 6 and
8 days respectively). Each group consisted of 10 mice.
was to enhance the immunogenicity of the subunit vaccine as well
as directing the immune response toward Th1.
Immunogenicity and protective efficacy of several T. gondii
recombinant antigens produced in bacteria have also been
performed against Toxoplasma infection in experimental mouse
models (Martin et al., 2004; Dziadek et al., 2009, 2012). It was
reported that alum adjuvant-formulated rGRA4 was a potential
multi-antigen vaccination candidate against chronic T. gondii
infection either alone or in combination with rROP2 which
were both produced in pQE expression vector. It protected
the vaccinated C57BL/6 and C3H mice against challenge with
ME49 strain through brain cyst reduction (Martin et al., 2004).
Meanwhile, vaccination of C3H/HeJ mice with rROP2 and
rROP4 which were expressed in pH is vector has been shown
to elicit mixed Th1/Th2-type immune response with specific IL-
2 production. These two antigens conferred partial protection
against challenge with DX strain (low virulent) with 46% brain
cysts reduction. It was also reported that combination of the
same rROP2 and rROP4 antigens with either rGRA4 or rSAG1
triggered both humoral (generation of high levels of IgG1 and
IgG2a) and cellular- (secretion of IFN-γ and IL-2) associated
immunity. The brain cysts loads in the vaccinated BALB/c mice
were greatly decreased (84 and 77% reduction respectively)
compared to PBS-injected mice (Dziadek et al., 2009, 2012).
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In this study, immunization of BALB/c mice with rGRA2 and
rGRA5 emulsified with complete/incomplete Freund’s adjuvant
(C/IFA) successfully triggered both humoral and cellular mixed
Th1/Th2-like immune responses, predominantly Th1 in the
vaccinated mice. The triggered immune response eventually
prolonged the mice’s survival rates against lethal challenge with
the virulent RH strain of T. gondii. These results confirmed
the antigenicity and immunogenicity of the two recombinant
proteins. However, Freund’s adjuvant is not suitable for use in
humans due to safety concerns (Stills, 2005).
Analysis of IgG antibody through SDS-PAGE/WB and ELISA
indicated that anti-GRA2 and anti-GRA5 IgG antibody was
produced in the immunized mice 2 weeks after prime injection.
The antibody levels increased with successive immunization
where antibody titres ranged from 1:409,600 to 1:819200
at 6 weeks post-prime injection. Meanwhile, anti-GRAs IgG
antibody detection was not observed in Native-PAGE/WB
probably due to protein folding which hinders the B-cell epitope.
Besides, relatively high levels of IgG1 and IgG2a were detected
in the immunized mice serum. The levels of these two antibody
isotypes are almost similar with slightly higher IgG1 than that
of IgG2a. Production of IgG1 is Th2 related, while IgG2a is
associated with Th1-driven immunity (Germann et al., 1995).
CD4+ Th1 cell populations are involved in B cells activation
and subclass-switched antibody production, whereby its absence
would lead to increased susceptibility to T. gondii (Harris
et al., 2001; Johnson and Sayles, 2002). Induction of humoral
immune response plays an essential role in the resistance
against Toxoplasma infection in which most of the B cell-
deficient mice survived from the infection post-treatment with
immune serum (Frenkel and Taylor, 1982). Significant protection
elicited through intraperitoneal injection of monoclonal anti-
T. gondii surface antigen antibody into mice against moderately
and highly virulent Toxoplasma infection further supports the
importance of humoral immunity in fighting toxoplasmosis
(Johnson et al., 1983). Other than conferring resistance to
T. gondii acute infection and controlling its chronic infection,
humoral immunity has been demonstrated to be important
in protecting rodents against other protozoa parasites as well,
such as Plasmodium berghei yoelii (Weinbaum et al., 1976) and
Trypanosoma cruzi (Rodriguez et al., 1981).
A study on the protective and resisting roles of B cells
response against lethal challenge with virulent strains of T. gondii
demonstrated that antigen-specific antibody inhibited host cell
active invasion by blocking the tachyzoites directly, preventing
them from attaching to the host cell and thus restricting
parasite propagation (Sayles et al., 2000). On the other hand,
antibody-coated tachyzoites could be destroyed by phagocytic
cells such as macrophage through passive phagocytosis (Sibley
et al., 1993). Positive correlation was observed between the high
titers of two IgG isotypes; IgG1 and IgG2a and the levels of
phagocytosis which eventually protected immunized mice against
S. pneumonia (Lefeber et al., 2003).
Earlier findings reported that monoclonal antibody against
T. gondii surface antigens successfully blocked tachyzoites
invasion and in vitro propagation as compared to monoclonal
antibody against antigens of T. gondii secretory organelles with
little or no effect on invasion (Johnson et al., 1983; Grimwood and
Smith, 1996). However, another study showed that phagocytic
cell (macrophage) invasion of T. gondii was inhibited by
monoclonal anti-GRA2 in the presence of complement (Cha
et al., 2001). At the same time, the monoclonal antibody partially
protected mice against RH strain tachyzoite infection mediated
by complement-dependent effector mechanism (Sayles et al.,
2000; Cha et al., 2001). This highlights the protective role played
by specific antibody.
Apart from humoral immunity, cell-mediated immunity is a
major protective response against intracellular T. gondii. The cell-
mediated immunity response is through specific T lymphocytes
activation (CD4+ and CD8+), especially Th1 response coupled
with IFN-γ production (Suzuki and Remington, 1988; Gazzinelli
et al., 1991; Parker et al., 1991; Sibley et al., 1993). Interferon-
gamma-mediated cytotoxic T lymphocyte (CTL) response
restraints the propagation and spreading of the parasite by
impeding the growth of actively dividing tachyzoites (acute
phase) and limiting reactivation of the encysted bradyzoites
(Pfefferkorn, 1984; Pfefferkorn et al., 1986; Suzuki et al., 1988;
Dillon et al., 1992; Zheng et al., 2013).
In this study, stimulated T-lymphocytes in the spleen cells of
rGRA2- and rGRA5-immunized mice proliferated significantly.
Interferon-gamma and IL-2 were two pro-inflammatory
cytokines that were secreted in large amount suggesting that
CD4+ Th1 and CD8+ cytotoxic T-cells were being triggered.
In addition, IL-4 and IL-10 were also produced but at relatively
low levels which are associated with CD4+ Th2 cells induction.
Besides fighting against T. gondii, these two anti-inflammatory
cytokines play a vital role in balancing and reducing the
deleterious inflammatory effect, especially of IFN-γ (Snapper
and Paul, 1987; Gazzinelli et al., 1991; Bessieres et al., 1997).
Humoral and cellular immune responses are interrelated
and synergistic instead of acting alone to mount protection
against any pathogen. Activated cytokine-secreting Th cells are
involved in the stimulation of antibody-producing B cells as
well as determining the switch of antibody isotype, either IgG1
or IgG2a in T-cell dependent immunity (Snapper and Paul,
1987; Germann et al., 1995). Th1-related IFN-γ induces IgG2a
generation and expression of the respective FcR1 on mouse
macrophage (equivalent to human monocyte FcR), suppressing
IgG1 synthesis at the same time. In other words, Th1 is
responsible for macrophage activation through stimulation of
pro-inflammatory cytokines (IFN-γ, TNF-α, IL-2) and IgG2a
antibody generation. The protective role of IFN-γ and IgG2a has
been demonstrated through opsonisation, complement-mediated
cell lysis and antibody-dependent cellular cytotoxicity (ADCC)
(Johnson et al., 1985; Snapper and Paul, 1987; Petersen et al.,
1998). On the other hand, Th2-related IL-4, which is also known
as B cell stimulatory factor-1 (BSF-1), possesses an antagonistic
effect to IFN-γ whereby it enhances IgG1 production and FcR2
expression on mouse macrophage (equivalent to natural killer
cell FcR in human) but suppresses IgG2a production (Perussia
et al., 1983; Snapper and Paul, 1987). Th2 stimulates development
of anti-inflammatory cytokines (IL-4, IL-5, IL-6, and IL-10) and
IgG1 antibody which leads to down regulation of macrophage
activity (Petersen et al., 1998).
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A study demonstrated that sterile protective immunity to
toxoplasmosis is possible if strong humoral and cellular immune
responses are successfully elicited and acting synergistically
whereby the survival rates of the infected mice will not
significantly increase in the absence of either antibody production
or T cell immunity (Frenkel and Taylor, 1982). Therefore, it
is deduced that the increase in the median survival time of
T. gondii-challenged mice from 6–8 days (non-immunized mice;
PBS and pRSET B-injected) to 16–16.5 days (immunized mice;
rGRA5 and rGRA2-injected) in this study might be resulted from
the interaction between antibody-producing B lymphocytes and
cytokine-producing T lymphocytes (Th1 and Th2).
The delayed onset of death observed in rGRA2 and rGRA5-
immunized mice might be due to the interplay between Th1
and Th2-driven responses as findings have shown that Th1-
related cytokine primarily IFN-γ causes early mortality whereas
Th2-related IL-4 and IL-10 diminish short-term fatality by
down regulating Th1 response and thus reducing the severe
inflammatory effect provoked by IFN-γ at the early acute phase
of toxoplasmosis (Roberts et al., 1996; Neyer et al., 1997; Petersen
et al., 1998). An increase in survival rate and decrease in necrosis
of the small intestine was observed in C57BL/6 mice treated
with monoclonal anti-IFN-γ antibody (Liesenfeld et al., 1996).
It has also been determined that secretion of IFN-γ is directly
proportional to the mortality rate of the infected mice (McLeod
et al., 1989). IL-4-deficient mice have higher susceptibility toward
acute Toxoplasma infection compared to the wild type due to
excessive IFN-γ secretion. In contrast, development of necrotic
lesions with free living tachyzoites has been seen in wild-type
mice but not in IL-4-deficient mice (Roberts et al., 1996). One of
the negative regulatory effects of IL-10 is to suppress macrophage
killing activity mediated by IFN-γ (Sibley et al., 1993). Infected
IL-10-depleted mice died during acute Toxoplasma infection
with relatively high levels of IFN-γ and IL-12 detected in their
serum. These mice were believed to have succumbed to lethal
immunopathology instead of parasitic infection as there was
no sign of significant T. gondii propagation (Gazzinelli et al.,
1996).
The overall results obtained in the present study are in
agreement with the results of previous studies. The recombinant
antigens triggered strong humoral and cellular Th1-dominating
immune response by up-regulating the development of antigen-
specific IgG antibody (IgG2a) and Th1-related cytokines
(IFN-γ and IL-2) (Golkar et al., 2007; Zhou et al., 2007).
Monophosphoryl lipid A (MPL) adjuvant-formulated rGRA2
had been shown to reduce brain cysts formation significantly in
the immunized CBA/J mice either alone or mixed with rGRA6,
thereby protecting against chronic T. gondii infection (Golkar
et al., 2007). Immunization of BALB/c mice with multi-antigenic
protein vaccine containing SAG1-GRA2 expressed in yeast host
successfully increased survival time of the vaccinated mice up to
15 days against lethal challenge with T. gondii RH strain (acute
infection) (Zhou et al., 2007).
Protective efficacy of GRA5 subunit vaccine against chronic
toxoplasmosis has been indicated by intranasal immunization in
combination with rGRA7 and rROP2 adjuvanted with cholera
toxin by reducing brain cyst formation of VEG strain by 58.3%
in BALB/c mice (Igarashi et al., 2008b). Nevertheless, this is
thus far the first report of evaluation of the immunity elicited
by GRA5 as a single-antigenic subunit vaccine candidate against
acute toxoplasmosis in the mouse model.
CONCLUSION
Subcutaneous injection of mice with subunit vaccines rGRA2
and rGRA5 successfully triggered humoral and cellular responses
which resulted in partial protection to the vaccinated mice against
parasitic lethal challenge. A combination of Th1/Th2-related
responses primarily Th1 was obtained with significant increased
production of IgG2a, IFN-γ, IL-2 and IgG1 but relatively low
level of IL-4 and IL-10. The encouraging findings obtained in
this study provide a basis for further investigation into the
development of a recombinant multi-antigenic candidate using
combination of GRA2-GRA5 for immunization against T. gondii
infection.
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